(Q36729180)

15 August 2017

Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians (English)

1 reference

15 August 2017

1 reference

7

Ernst J Kuipers

1 reference

15 August 2017

Nicole G Hunfeld

1

1 reference

15 August 2017

Ron A Mathot

2

1 reference

15 August 2017

Daan J Touw

3

1 reference

15 August 2017

Ron H van Schaik

4

1 reference

15 August 2017

Paul G Mulder

5

1 reference

15 August 2017

Paul F Franck

6

1 reference

15 August 2017

William P Geus

8

1 reference

15 August 2017

language of work or name

English

0 references

publication date

30 January 2008

1 reference

British Journal of Clinical Pharmacology

15 August 2017

1 reference

15 August 2017

65

1 reference

15 August 2017

5

1 reference

15 August 2017

752-760

1 reference

Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432487

Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432487

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432487

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432487

Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432487

Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432487

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432487

Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432487

The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432487

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2432487

An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.03094.X

Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects

21 January 2018

1 reference

12 December 2020

Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations

1 reference

12 December 2020

CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms

1 reference

12 December 2020

Determination of omeprazole and metabolites in plasma and urine by liquid chromatography

1 reference

12 December 2020

Day-to-day variation of 24-hour intragastric acidity

1 reference

12 December 2020

High-performance liquid chromatographic determination of the H+/K+ ATPase inhibitor (BY 1023/SK&F 96,022) and its sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean-up

1 reference

12 December 2020

Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography

1 reference

12 December 2020

Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism

1 reference

12 December 2020

CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans

1 reference

12 December 2020

CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole

1 reference

12 December 2020

10.1111/J.1365-2125.2007.03094.X

Identifiers

DOI

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

18241283

1 reference